BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 626972)

  • 1. Immunotherapy of an established rat mammary adenocarcinoma (13762A) with intratumor injection of Corynebacterium parvum.
    Kreider JW; Bartlett GL; Purnell DM; Webb S
    Cancer Res; 1978 Mar; 38(3):689-92. PubMed ID: 626972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conditions for effective Bacillus Calmette-Guérin immunotherapy of postsurgical metastases of 13762A rat mammary adenocarcinoma.
    Kreider JW; Bartlett GL; Boyer CM; Purnell DM
    Cancer Res; 1979 Mar; 39(3):987-92. PubMed ID: 427785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Destruction of regional lymph node metastases of rat mammary adenocarcinoma 13762A by treatment with Corynebacterium parvum.
    Kreider JW; Bartlett GL; Purnell DM; Webb S
    Cancer Res; 1978 Dec; 38(12):4522-6. PubMed ID: 719637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of T-cell subsets in the destruction of established metastases of 13762A rat mammary adenocarcinoma.
    Howell LE; Kreider JW; Bartlett GL
    J Natl Cancer Inst; 1986 Jul; 77(1):187-93. PubMed ID: 3487670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dose and schedule of immune stimulant on efficacy of combination Corynebacterium parvum-cyclophosphamide treatment for a murine mammary adenocarcinoma.
    Purnell DM; Bartlett GL; Kreider JW
    Cancer Res; 1979 Jan; 39(1):1-5. PubMed ID: 761179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of C. parvum on intratumor immunity to the T1699 mammary adenocarcinoma.
    Haskill S; Ritter F; Becker S
    J Immunol; 1980 Jul; 125(1):454-8. PubMed ID: 6247400
    [No Abstract]   [Full Text] [Related]  

  • 7. Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma.
    Purnell DM; Bartlett GL; Kreider JW; Biro TG
    Cancer Res; 1977 Apr; 37(4):1137-40. PubMed ID: 844041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic adoptive transfer of immunity to 13762A rat mammary adenocarcinoma.
    Boyer CM; Kreider JW; Bartlett GL
    Cancer Res; 1981 Jun; 41(6):2394-400. PubMed ID: 6972251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative antitumor effects of Corynebacterium parvum, Bordetella pertussis, Bacillus Calmette-Guérin, and levamisole alone or in combination with cyclophosphamide in the CaD2 murine mammary adenocarcinoma system.
    Purnell DM; Bartlett GL; Kreider JW; Biro TG; Kontra J
    Cancer Res; 1979 Dec; 39(12):4838-42. PubMed ID: 498111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased immunogenicity of a spontaneous variant clone of the 13762A rat mammary adenocarcinoma.
    Kreider JW; Bartlett GL
    J Natl Cancer Inst; 1985 Jul; 75(1):141-9. PubMed ID: 3859687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of killed Corynebacterium parvum suspensions in a murine mammary adenocarcinoma CaD2) system.
    Purnell DM; Otterstrom JR; Bartlett GL; Kreider JW
    J Natl Cancer Inst; 1976 Jun; 56(6):1171-5. PubMed ID: 994219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental cancer immunotherapy: comparison of tumor rejection if F344 rats given live Mycobacterium bovis (Strain BCG) and killed Corynebacterium parvum.
    Likhite VV
    J Natl Cancer Inst; 1976 May; 56(5):985-9. PubMed ID: 994209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lasting rejection of mammary adenocarcinoma cell tumors in DBA-2 mice with intratumor injection of killed Corynebacterium parvum.
    Likhite VV; Halpern BN
    Cancer Res; 1974 Feb; 34(2):341-4. PubMed ID: 4810906
    [No Abstract]   [Full Text] [Related]  

  • 14. Rejection of tumors and metastases in Fischer 344 rats following intratumor administration of killed Corynebacterium parvum.
    Likhite VV
    Int J Cancer; 1974 Nov; 14(5):684-90. PubMed ID: 4459281
    [No Abstract]   [Full Text] [Related]  

  • 15. Rejection of mammary adenocarcinoma cell tumors in DBA/2 mice immunocompromised by thymectomy and treatment with antithymocyte serum.
    Likhite VV
    J Immunol; 1975 Jun; 114(6):1736-42. PubMed ID: 1092759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of an intracerebral rat brain tumor with Corynebacterium parvum and radiation.
    Douple EB
    Natl Cancer Inst Monogr; 1977 Dec; 46():179-84. PubMed ID: 206836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of Corynebacterium parvum, Brucella abortus extract, Bacillus Calmette-Guérin, glucan, levamisole, and tilorone with or without cyclophosphamide on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model.
    Fisher B; Gebhardt M
    Cancer Treat Rep; 1978 Nov; 62(11):1919-30. PubMed ID: 728912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of immunotherapeutic agents on the progression of spontaneously arising, metastasizing rat mammary adenocarcinomas of varying immunogenicities.
    Greager JA; Baldwin RW
    Cancer Res; 1978 Jan; 38(1):69-73. PubMed ID: 618584
    [No Abstract]   [Full Text] [Related]  

  • 19. Relationship between intradermal tumor suppression and tumor immunity.
    Bartlett GL; Kreider JW; Purnell DM
    J Natl Cancer Inst; 1976 Dec; 57(6):1297-303. PubMed ID: 794505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of cancer using Corynebacterium parvum: similarity of two preparations in four animal tumor models.
    Bartlett GL; Kreider JW; Purnell DM
    Cancer; 1980 Aug; 46(4):685-91. PubMed ID: 7397633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.